Design Therapeutics Inc stock is traded at $10.63, with a volume of 315,622. It is up +2.80% in the last 24 hours and down -13.86% over the past month. Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
Previous Close:
$10.34
Open:
$10.67
24h Volume:
315,622
Relative Volume:
1.03
Market Cap:
$665.24M
Revenue:
-
Net Income/Loss:
-$69.71M
P/E Ratio:
-
EPS:
-$1.19
Net Cash Flow:
-$54.12M
1W Performance:
-4.06%
1M Performance:
-13.86%
6M Performance:
-19.29%
1Y Performance:
+70.35%
1-Day Range:
$10.31$10.79
1-Week Range:
$10.13$11.43
52-Week Range:
$6.16$17.25
Design Therapeutics Inc Stock (DSGN) Company Profile
Name
Design Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
858-293-4900Address
6005 HIDDEN VALLEY ROAD, CARLSBAD, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS